Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04561206 |
|
Recruitment Status :
Recruiting
First Posted : September 23, 2020
Last Update Posted : September 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Relapsed Classic Hodgkin Lymphoma | Drug: Brentuximab Vedotin Biological: Nivolumab | Phase 2 |
PRIMARY OBJECTIVE:
I. Assess the durability of response to brentuximab vedotin (BV) plus nivolumab (nivo) by 24-month progression-free survival (PFS) in participants (with relapsed/refractory classical Hodgkin lymphoma (RcHL) after frontline therapy) who achieved early complete metabolic response (CMR) (CMR after 4 cycles).
SECONDARY OBJECTIVES:
I. Estimate CMR and overall response rate (ORR) after 4 cycles and at the end of BV-nivo therapy.
II. Estimate the PFS and overall survival (OS) for the entire cohort and for subgroups of patients defined by their response.
III. Estimate the PFS and OS separately for responders who did and did not receive radiotherapy.
IV. Evaluate the toxicities of BV-nivo in the study population.
EXPLORATORY OBJECTIVES:
I. Estimate the second PFS after salvage therapy for patients who progress after study therapy, and for the subset of these patients who proceeded to autologous stem cell transplant (ASCT).
II. Explore the association between clinical outcomes and pathological tumor characteristics.
III. Explore the association between clinical outcomes and circulating tumor deoxyribonucleic acid (ctDNA) characteristics (mutation profile, kinetics of clearance).
OUTLINE:
Patients receive brentuximab vedotin intravenously (IV) over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and 6, 12, 18, 24, 36, 48, and 60 months.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 31 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without Stem Cell Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma |
| Actual Study Start Date : | November 12, 2021 |
| Estimated Primary Completion Date : | October 2, 2024 |
| Estimated Study Completion Date : | October 2, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment (brentuximab vedotin, nivolumab)
Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity.
|
Drug: Brentuximab Vedotin
Given IV
Other Names:
Biological: Nivolumab Given IV
Other Names:
|
- Progression-free survival (PFS) at 24 months in patients who achieve complete metabolic response (CMR) after 4 cycles of treatment [ Time Frame: From start of protocol treatment to time of disease relapse/progression or death due to any cause, assessed at 24 months ]Estimated using Kaplan-Meier product limit method.
- Complete metabolic response (CMR) rate [ Time Frame: After 4 or 8 cycles (each cycle is 21 days) ]Defined as the proportion of response-evaluable participants that achieve a best response of CMR with brentuximab vedotin (BV)-nivolumab (Nivo) therapy. Will be estimated along with the 95% exact binomial confidence interval.
- Overall response rate (ORR) [ Time Frame: After 4 or 8 cycles (each cycle is 21 days) ]defined as the proportion of response-evaluable participants that achieve a best response of either CMR or partial metabolic remission (PMR) with BV-Nivo therapy. Will be estimated along with the 95% exact binomial confidence interval.
- Overall survival (OS) [ Time Frame: From start of protocol treatment to time of death due to any cause, assessed up to 5 years (each cycle is 21 days) ]Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median PFS/OS will be estimated when available. PFS and OS will be estimated for the entire cohort, for subgroups defined by response, and for responders who did and did not receive radiotherapy.
- PFS [ Time Frame: From start of protocol treatment to time of disease relapse/progression or death due to any cause, whichever occurs earlier, assessed up to 5 years(each cycle is 21 days) ]Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median PFS/OS will be estimated when available. PFS and OS will be estimated for the entire cohort, for subgroups defined by response, and for responders who did and did not receive radiotherapy.
- Incidence of adverse events [ Time Frame: Up to 30 days post-treatment ]Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Observed toxicities of BV-Nivo therapy will be summarized by type (organ affected or laboratory determination such as absolute neutrophil count), severity, and attribution.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Documented informed consent of the participant and/or legally authorized representative
- Assent, when appropriate, will be obtained per institutional guidelines
-
Be willing to provide tissue (either from a fresh core or excisional biopsy performed as standard of care, or from archival tissue) of a biopsy that was performed after frontline systemic therapy, and prior to starting protocol therapy
- If unavailable, exceptions may be granted with study principal investigator (PI) approval
- Eastern Cooperative Oncology Group (ECOG) =< 2
- Histologically confirmed diagnosis of classical Hodgkin lymphoma (excluding nodular lymphocyte predominant Hodgkin lymphoma) according to the World Health Organization (WHO) classification, with hematopathology review at the participating institution
- Relapsed or refractory disease after no more than 1 line of prior therapy (not counting radiotherapy). However, a maximum of 5 patients with primary refractory disease may be enrolled in this study.
Note: Patients who received BV or an anti-PD-1/PD-L1 agent as part of frontline therapy are eligible if they achieved a CMR with frontline therapy and have not relapsed within 6 months from the end of frontline therapy Relapse must have been confirmed histologically (with hematopathology review at the participating institution)
- Not a candidate for ASCT, based on age, co-morbidities, or patient preference. The reason for ASCT non-candidacy must be documented in the Case Report Form and verified by the site PI
- Measurable disease (at least one non-bony fludeoxyglucose F-18 [FDG]-avid lesion >= 1.5 cm in long axis)
-
Absolute neutrophil count (ANC) >= 1,000/mm^3
- NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement
-
Platelets >= 50,000/mm^3
- NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement
- Hemoglobin >= 8 g/dL (no transfusion allowed within 3 days prior to screening)
- Total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< 1.5 x ULN for patients with Gilbert's disease
- Aspartate aminotransferase (AST) =< 2.5 x ULN
- Alanine aminotransferase (ALT) =< 2.5 x ULN
- Creatinine clearance of >= 40 mL/min per 24 hour urine test or the Cockcroft-Gault formula
- Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Agreement by women and men of childbearing potential* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 5 months (women) or 7 months (men) after the last dose of protocol therapy
- Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)
Exclusion Criteria:
- Concomitant investigational therapy
- Live vaccine within 30 days prior to day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette-Guerin [BCG], oral polio vaccine, and oral typhoid)
- Grade >= 2 peripheral neuropathy
- History of prior >= grade 3 hypersensitivity to either brentuximab vedotin or nivolumab
- Known active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis
-
History of another primary malignancy that has not been in remission for at least 3 years, with the following exceptions:
- Non-melanoma skin cancer treated with curative intent
- In situ cervical cancer
- If the malignancy is expected to not require any treatment for at least 2 years (this exception should be discussed with the study PI)
-
Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration. Exceptions are:
- Inhaled or topical steroids and
- Adrenal replacement doses > 10 mg daily prednisone equivalents in the absence of active autoimmune disease
- History of progressive multifocal leukoencephalopathy (PML)
- Prior diagnosis of inherited or acquired immunodeficiency
- Active pneumonitis or interstitial lung disease
-
Active, known or suspected autoimmune disease. The following are exceptions:
- Vitiligo
- Psoriasis not requiring systemic treatment
- Hemolytic anemia associated with the lymphoma
- Type I diabetes mellitus, if adequately controlled with therapy
- Thyroid disease, if adequately controlled with therapy
- Conditions not expected to recur in the absence of an external trigger (such exceptions should be discussed with the study PI)
-
Active history of:
- Hepatitis B (hepatitis B virus [HBV]) or C (hepatitis C virus [HCV]) infection. Patients with past HBV infection (defined as negative hepatitis B surface antigen [HBsAg] and positive hepatitis B core antibody [HBcAb]) are eligible if HBV DNA is undetectable. Patients who are positive for HCV antibody are eligible if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA)
- Human immunodeficiency virus (HIV) infection. Subjects who have an undetectable or unquantifiable human immunodeficiency virus (HIV) viral load with CD4 >= 200 and are on highly active antiretroviral therapy (HAART) medication are allowed. Testing to be done only in patients suspected of having infections or exposures
- History of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association class III-IV within 6 months prior to day 1 of protocol therapy
- Pregnant or breastfeeding
- Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04561206
| United States, California | |
| City of Hope Medical Center | Recruiting |
| Duarte, California, United States, 91010 | |
| Contact: Alex F. Herrera 626-256-4673 ext 62405 aherrera@coh.org | |
| Principal Investigator: Alex F. Herrera | |
| United States, Illinois | |
| University of Chicago Cancer Research Center | Recruiting |
| Chicago, Illinois, United States, 60637 | |
| Contact: Justin Kline, MD 773-702-5550 jkline@medicine.bsd.uchicago.edu | |
| United States, Massachusetts | |
| Dana-Farber Cancer Institute | Recruiting |
| Boston, Massachusetts, United States, 02215 | |
| Contact: Philippe Armand, MD, PhD 617-632-2305 philippe_armand@dfci.harvard.edu | |
| Contact: Philippe Armand 617-632-2305 philippe_armand@dfci.harvard.edu | |
| United States, New Jersey | |
| Hackensack University Medical Center/John Theurer Cancer Center | Recruiting |
| Hackensack, New Jersey, United States, 07601 | |
| Contact: Tatyana Feldman, MD 201-996-3033 Tatyana.Feldman@hackensackmeridian.org | |
| Contact: Tatyana Feldman 201-996-3033 Tatyana.Feldman@hackensackmeridian.org | |
| United States, Tennessee | |
| Sarah Cannon Research Institute | Recruiting |
| Nashville, Tennessee, United States, 37203 | |
| Contact: Ian W Flinn, MD, PhD 615-986-7600 iflinn@tnonc.com | |
| Principal Investigator: | Alex F Herrera | City of Hope Medical Center |
| Responsible Party: | City of Hope Medical Center |
| ClinicalTrials.gov Identifier: | NCT04561206 |
| Other Study ID Numbers: |
20147 NCI-2020-05332 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 20147 ( Other Identifier: City of Hope Medical Center ) P30CA033572 ( U.S. NIH Grant/Contract ) |
| First Posted: | September 23, 2020 Key Record Dates |
| Last Update Posted: | September 15, 2023 |
| Last Verified: | September 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Lymphoma Hodgkin Disease Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents, Immunological Nivolumab Brentuximab Vedotin |
Antibodies Immunoglobulins Antibodies, Monoclonal Immunoconjugates Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Immunotoxins |